Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis

PDF) Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

Pathogens, Free Full-Text

Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis - eBioMedicine

Biomedicines, Free Full-Text

Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study - The Lancet Healthy Longevity

Immunogenicity of two doses of BNT162b2 and mRNA‐1273 vaccines for solid cancer patients on treatment with or without a previous SARS‐CoV‐2 infection - La Verde - 2023 - International Journal of Cancer

Vaccines, Free Full-Text

Pathogens, Free Full-Text

Immunity to SARS‐CoV‐2 induced by infection or vaccination - Castro Dopico - 2022 - Journal of Internal Medicine - Wiley Online Library

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine